Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56754 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL56753 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL6684772 | 0.88 | CA1 (0.49) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL19227630 | 0.88 | CA1 (0.58) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL24387611 | 0.85 | CA1 (0.49) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL24387604 | 0.85 | CA1 (0.49) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL9506672 | 0.84 | CYP2D6 (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL7434716 | 0.84 | PLA2G10 (0.51) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL24900084 | 0.84 | CA1 (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL2385476 | 0.83 | CTSK (0.49) | CTSSCTSKCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250037039-A1 | MOLECULAR DATA STORAGE USING COST-FREE MOLECULAR LIBRARIES | BROWN UNIVERSITY | 2025-01-30 | — | — | US | disclosed |
| EP-4237086-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230027270-A1 | METHODS OF CHEMICAL COMPUTATION | BROWN UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| WO-2023283831-A1 | VIRUS MAIN PROTEASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE | 上海药明康德新药开发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20160176894-A1 | TAXANE AND ABEO-TAXANE ANALOGS | Arbor Therapeutics, LLC (US) | 2016-06-23 | — | — | US | disclosed |
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20030212250-A1 | Improved proteolytic enzyme resistance | SEEBACH DIETER (CH) | 2003-11-13 | — | — | US | disclosed |
| US-6617425-B1 | Of given formula; stable in solution and resistant to proteolytic degradation; use in drug formulations | NOVARTIS AG (CH) | 2003-09-09 | — | — | US | disclosed |
| EP-0906272-B1 | PEPTIDES | NOVARTIS AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-0906272-A2 | PEPTIDES | Novartis AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997047593-A2 | PEPTIDES | NOVARTIS AG (CH) | 1997-12-18 | — | — | WO | disclosed |
| US-5502036-A | VIRICIDES | BIOMEGA BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-03-26 | — | — | US | disclosed |
| EP-0411334-A1 | Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | CTSS 3490/4885CTSK 4240/4885CTSL 4205/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSS 4022/4885CTSK 4661/4885CTSL 1563/4885 |
| US-20030212250-A1 | Improved proteolytic enzyme resistance | PEPD, ANPEP, PREP | CTSS 59/4885CTSK 84/4885CTSL 69/4885 |
| US-20160176894-A1 | TAXANE AND ABEO-TAXANE ANALOGS | AR, THPO, DPYD | CTSS 4405/4885CTSK 3223/4885CTSL 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.